Predictive Oncology Inc. (POAI): Business Model Canvas [Dec-2025 Updated]

You're digging into a company that has completely flipped the script on biotech financing, and as an analyst, I find this pivot compelling: Predictive Oncology Inc. (POAI) is operating on a dual model funded by a massive digital asset treasury. Forget pure R&D; this strategy pairs their 92% accurate PeDAL™ AI drug discovery platform with the active management of a strategic compute reserve, which held about $152.8 million in ATH tokens as of November 2025. It's a high-wire act balancing cutting-edge oncology-like their ChemoFx® assay-with the volatile world of crypto monetization, especially when their total revenue for the first nine months of 2025 was only $116,610. Let's map out exactly how this unique structure is supposed to generate returns below.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Key Partnerships

You're looking at the core relationships that fuel Predictive Oncology Inc.'s dual-track strategy-biotech innovation and digital asset infrastructure. Here's the breakdown of the key players as of late 2025.

The agreement with Yorkville Advisors Global, LP, via YA II PN, LTD, established a flexible funding mechanism. Predictive Oncology has the right to sell up to $10 million worth of common stock under this standby equity purchase agreement (SEPA), which was entered into in July 2025.

For the digital asset treasury strategy, DNA Holdings Venture, Inc. serves as the strategic advisor and consultant. Shawn Matthews, CEO of DNA Holdings Venture, Inc., joined the Predictive Oncology Board of Directors in October 2025. This strategy is centered on the Aethir (ATH) token.

The collaboration with the Aethir network is central to the Strategic Compute Reserve initiative. Predictive Oncology received aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of locked and unlocked ATH with an aggregate notional value of approximately $292.7 million from private placements pricing around October 2, 2025. As of November 10, 2025, the holding was approximately 5.70 billion ATH, valued at about $152.8 million, based on a price of $0.0268 per ATH. Of that holding, 3.7 billion ATH are locked.

The partnership with Every Cure, announced in September 2025, focuses on drug repurposing. Predictive Oncology contributes its AI platform, PEDAL, which predicts patient tumor drug response with 92% accuracy. This is applied to data from Predictive Oncology's biobank, which contains more than 150,000 tumor samples.

Integra Therapeutics is a partner to advance gene writing tools for cancer therapies, stemming from a collaboration that started in March 2023. Predictive Oncology contributes protein expression experience and uses its proprietary automated technology, high-throughput self-interaction chromatography (HSC™).

Here's a quick look at the scale and financial backing of the most recent strategic relationships:

The company's AI platform, PEDAL, shows 92% accuracy in predicting tumor responses, which is the core asset leveraged with Every Cure.

• DNA Holdings Venture, Inc. role: Strategic advisor for the digital asset treasury.
• Yorkville Advisors funding structure: No warrants or derivatives attached to the SEPA.
• Aethir ATH holding breakdown: 2.0 billion ATH were unlocked as of November 10, 2025.
• Integra Therapeutics focus: Engineering next-generation gene writing tools.

Finance: review the impact of the $50.8 million cash proceeds from the September 2025 PIPEs on the Q4 2025 cash position by next Tuesday.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Key Activities

You're looking at the core engine of Predictive Oncology Inc. (POAI) right now, which is a fascinating mix of biotech, AI, and, quite recently, digital asset management. Here's the breakdown of what the company is actively doing to drive value, grounded in their late 2025 figures.

Developing and optimizing the PeDAL™ AI/ML drug discovery platform.

The PeDAL platform is central to the science. It's the brain that processes the massive amount of biological data the company sits on. This activity is about refining that predictive power to make drug selection more efficient for partners.

• PeDAL platform reportedly predicts with 92% accuracy if a tumor sample will respond to a specific drug compound.
• The platform is powered by the company's biobank, which holds more than 150,000 assay-capable heterogenous human tumor samples.

Active management and monetization of the 5.70 billion ATH token reserve.

This is the newer, highly visible activity following the major capital raise. It's about turning a treasury asset into an active part of the business model, aiming to support AI infrastructure needs. The sheer scale of the investment is what makes this a key activity.

Here's the quick math on the digital asset treasury as of mid-November 2025:

The initial move to establish this reserve involved raising an aggregate of approximately $344.4 million through private placements, which included both cash proceeds of approximately $51.7 million and in-kind contributions of ATH tokens. For Q3 2025, the initiation of this strategy resulted in a reported loss on derivative instruments of $74.4 million. The stated goal is to target high single-digit returns on these digital assets by FY'26.

Conducting wet lab experiments using proprietary 3D tumor models.

This activity bridges the AI predictions with physical validation, which is crucial for de-risking drug candidates. The company is also using these models for specific external collaborations.

• In Q1 2025, revenue was positively impacted by the completion of a tumor-specific 3D model in the quarter ending March 31, 2025.
• During Q2 2025, Predictive Oncology successfully developed two distinct and unique 3D liver toxicity models exclusively for Labcorp.

Commercializing the ChemoFx® drug response assay in the US and Europe.

ChemoFx® is the company's validated live cell assay designed to help oncologists select effective chemotherapy treatments, moving away from trial-and-error. This is a direct revenue-generating activity.

• The European launch of the ChemoFx® assay was announced in Q1 2025.
• The assay is the primary method used to populate the company's biobank of over 150,000 patient samples.
• The company was preparing for a de novo launch in Europe in Q4 2025, while continuing to expand availability in the U.S..

Identifying and prioritizing existing drugs for new cancer indications.

This drug repurposing effort uses the AI platform on publicly available data for abandoned or discontinued drugs, which is a lower-cost path to potential new therapies. They formalized this with a partnership.

• Predictive Oncology announced a strategic collaboration with Every Cure to support this identification process.
• For Q1 2025, the initial screening identified three compounds warranting further exploration in new indications: Afuresertib (breast), Alisertib (colon), and Entinostat (colon).

Finance: draft 13-week cash view by Friday.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Key Resources

You're looking at the core assets that power Predictive Oncology Inc.'s entire operation right now. These aren't just line items; they're the engine for their AI-driven drug discovery and their newer digital asset strategy. Honestly, you can't separate the two anymore.

The PeDAL™ AI platform is central. This proprietary technology is scientifically validated to predict if a tumor sample will respond to a certain drug compound with 92% accuracy. That level of precision helps drug developers select better drug-tumor-type combinations before expensive wet lab work even starts.

A significant, and newer, key resource is the Strategic Compute Reserve, which is built around their holdings of the Aethir (ATH) token. This reserve is designed to support the monetization of AI infrastructure. Here's the quick math on that asset as of November 10, 2025, based on the latest reports.

What this estimate hides is the operational potential; Predictive Oncology Inc. functions as an operator on the Aethir ecosystem using these assets, which is a different kind of resource than just a passive holding. Still, the balance sheet impact is clear.

Next, you have the foundation of their predictive models: the biobank. This is one of the largest privately held collections available for this kind of research. It's the real-world data feeding the AI.

• Largest privately held biobank of over 150,000 human tumor samples.
• Over 200,000 pathology slides supporting the sample data.
• Data history spanning 20 years of actionable drug and tumor response information.

To process and validate the data from this massive resource, Predictive Oncology Inc. maintains its wholly owned CLIA-certified laboratory facility. This physical asset allows for the necessary clinical assays and in-vitro testing to complement the in silico (computer-based) predictions made by PeDAL™. It's the tangible link between the AI prediction and the wet lab validation required by partners.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Value Propositions

You're looking at how Predictive Oncology Inc. (POAI) is positioning its core offerings in late 2025. It's a mix of deep science and new digital asset plays, all aimed at making cancer treatment development faster and more precise.

Accelerating preclinical drug discovery from years to months

The traditional path for drug discovery is a long haul. Predictive Oncology Inc. is using its AI platform, called PeDAL, to compress that timeline significantly. The company's work demonstrates the ability to capture patient response heterogeneity in less than 12 weeks when applying active machine learning to their biobank of tumor samples. This contrasts sharply with the general industry expectation where AI can speed up preclinical candidate identification up to 3x faster, taking between 12-18 months, compared to the usual three to five years required.

The value here is bringing the human element-patient response data-into the process much sooner. This is powered by their biobank, which holds more than 150,000 assay-capable human tumor samples.

Reducing drug development costs through AI-driven drug repurposing

Repurposing existing, often abandoned, drugs is a major cost-saver. Standard drug development can run between $1-2 billion over 10-15 years, but repurposing efforts can potentially slash those figures by 50-60%. Predictive Oncology Inc. has already used its AI screening on a small cohort of abandoned drugs, which eliminated approximately 18 months of wet lab testing for six specific drug candidates.

Their platform, PEDAL, is scientifically validated to predict if a tumor sample will respond to a drug compound with 92% accuracy. This informed selection de-risks the process substantially. Here's a look at the initial drug repurposing hits identified:

The company reported identifying three compounds for further exploration in colon and breast cancer as of Q1 2025.

Offering personalized cancer treatment prediction with the ChemoFx® assay

The ChemoFx® assay is Predictive Oncology Inc.'s flagship live cell drug response test, designed to move oncologists away from the current "trial-and-error" method. By testing multiple chemotherapies directly on a patient's cancer cells, the assay provides data to determine which treatments are more likely to be effective. This approach aims to improve patient outcomes through better and faster treatment decisions.

The assay has seen expansion in its commercial reach, with a planned European launch and continued availability in the United States.

• Initial focus: Ovarian and other gynecological cancers.
• Goal: Determine which chemotherapies are more likely to be effective.
• Benefit: Eliminates the current "trial-and-error" approach.

Providing high-performance, enterprise-grade AI compute access via Aethir

Predictive Oncology Inc. is building what it calls the world's first Strategic Compute Reserve, powered by Aethir's decentralized GPU network. This is intended to democratize access to AI infrastructure that has historically been limited by high costs and shortages.

The company initiated this strategy following private placements that delivered approximately $343.5 million in total value, broken down into approximately $50.8 million in cash proceeds and $292.7 million in notional ATH contributions. As of November 10, 2025, Predictive Oncology held approximately 5.70 billion ATH, valued at about $152.8 million based on a price of $0.0268 per ATH. Of that holding, 3.7 billion ATH are locked.

The underlying Aethir network supports enterprise-grade compute using leading Nvidia hardware, including the H100, H200, B200, and B300. The network itself spans more than 435,000 GPU containers across over 200 locations in 93 countries.

You're looking at a company that secured $3.1 million in cash as of March 31, 2025, up from $611,822 at the end of 2024, following the sale of its Skyline Medical assets to focus on this core AI/compute strategy.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Customer Relationships

Direct, high-touch consulting and collaboration with pharmaceutical R&D teams is supported by specific, data-driven engagements.

Predictive Oncology Inc. successfully developed two distinct and unique 3D liver toxicity models exclusively for Labcorp, a global leader of innovative and comprehensive laboratory services, in the second quarter of 2025. This involved both a human and a rat model, representing the liver microenvironment for drug metabolism and toxicity evaluation. Also, in March 2025, the company used its active machine learning platform in partnership with the Natural Products Discovery Core (NPDC) at the University of Michigan Life Sciences Institute to develop predictive models derived from 21 unique compounds. The AI platform, PEDAL, claims to predict medicine efficacy on tumor samples with 92% accuracy. The company also reported that after measuring 7% of possible wet lab experiments, its predictive ML model covered 73% of all experiments, virtually eliminating up to two years of laboratory testing in certain scenarios.

Strategic, long-term partnerships for co-development and licensing are a key focus area for funding growth initiatives.

The company is actively pursuing business development opportunities with leading biopharmaceutical firms to leverage its AI capabilities. The $10 million SEPA with Yorkville Advisors is explicitly intended to enable progress on these initiatives.

Automated service delivery for AI compute power via the Aethir network is now integrated into the business structure through a digital asset strategy.

Predictive Oncology Inc. expanded its business to include active digital asset management focused on ATH, the native utility token of the Aethir network, as of December 2025. This strategy was supported by two private placements that resulted in aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of locked and unlocked ATH with an aggregate notional value of approximately $292.7 million. As of November 10, 2025, the company held approximately 5.70 billion ATH, which had a market value of approximately $152.8 million, based on a price of $0.0268 per ATH. This is intended to allow Predictive Oncology to function as an operator on the Aethir ecosystem to satisfy enterprise demand for compute.

Clinical support for oncologists using the ChemoFx® assay is being aggressively expanded.

ChemoFx® is the proprietary live-cell tumor profiling assay that measures chemotherapy responses in vitro using a patient's own cells to provide personalized guidance for treatment selection. This assay was the primary method by which the company acquired more than 150,000 patient tumor samples, which feeds its biobank.

• Preparing for aggressive market expansion in the U.S. and de novo Launch in Europe as of Q2/Q3 2025.
• Initial focus for the treatment selection marker and tumor profiling assay is on ovarian and other gynecological cancers.
• The assay helps oncologists determine effective chemotherapies, eliminating the current "trial-and-error" approach.

The company reported total revenue of $110,310 for the first quarter ended March 31, 2025. The decrease in revenue for Q2 2025 to $2,682 was primarily due to decreased sales of tumor-specific 3D models and 3D kits.

Finance: review the cash burn rate against the $10 million SEPA funding availability by end of Q4 2025.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Channels

You're looking at how Predictive Oncology Inc. (POAI) gets its value propositions-from AI drug discovery to its new digital asset strategy-into the hands of customers and stakeholders as of late 2025. The channels have definitely shifted, moving beyond just lab services to a heavy focus on digital infrastructure partnerships.

Direct sales and business development teams targeting biopharma executives

This channel remains critical for the core oncology business, specifically for driving adoption of the ChemoFx® assay and securing data licensing or drug repurposing collaborations. While we don't have a headcount for the direct sales force, we can look at the associated spending to gauge the effort behind this push. Sales and marketing expenses for the second quarter of 2025 hit $268,959, up from $134,186 in the comparable period in 2024, largely due to increased fees for digital marketing consultants as they push for market expansion. Also, general and administrative expenses, which cover overhead for these efforts, were $2.6 million in the third quarter of 2025. The company is actively exploring strategic partnerships with biopharmaceutical companies to advance its drug repurposing candidates, such as the three identified compounds: Afuresertib, Alisertib, and Entinosta. Honestly, this channel is where the traditional science meets the market.

Digital asset platforms and the Aethir network for compute services

This is the newer, high-profile channel, positioning Predictive Oncology Inc. as an operator on the Aethir ecosystem to monetize its Strategic Compute Reserve. This strategy was funded by massive capital raises in late 2025. The network itself is substantial, spanning more than 435,000 GPU containers across 200+ locations in 93 countries, supporting hardware like Nvidia H100, H200, B200, and B300. The channel's success is tied to the value of the assets acquired to operate within it. Here's the quick math on the holdings as of November 10, 2025:

The plan is to drive a high single-digit yield on these digital assets by FY'26 through staking and GPU leasing, which is how they intend to generate booked revenue from this channel.

Clinical laboratory network for ChemoFx® assay distribution

The ChemoFx® assay distribution channel is focused on clinical utility, helping oncologists select better chemotherapy treatments. The company is aggressively advancing its market expansion for this flagship live cell drug response assay. They anticipated a de novo launch in Europe in the fourth quarter of 2025, complementing its ongoing U.S. availability. This assay is deeply integrated with their AI platform, as the data generated feeds back into their models. You should know that the foundation of this capability rests on their extensive biobank, which contains over 150,000 tumor samples across 137 types of cancer. The assay initially targets ovarian and other gynecological cancers, with plans to include other major tumor types over time.

Investor relations for capital raising and strategic financing

This channel is about securing the necessary capital to fund operations and execute the new digital asset strategy. The most significant recent event was the closing of two private investment in public equity (PIPE) transactions on October 7, 2025. This was a major influx of funding to support the Aethir (ATH) treasury strategy. The total aggregate raised was approximately $343.5 million. What this estimate hides is the split between cash and crypto value, which is important for understanding the immediate liquidity versus the strategic asset base:

• Cash Gross Proceeds: Approximately $50.8 million.
• In-Kind ATH Contributions (Notional Value): Approximately $292.7 million.
• In-Kind ATH Contributions (Discounted Value): Roughly $173.3 million.

This financing was crucial; following the closing, Predictive Oncology Inc. stated its stockholders' equity exceeded $2.5 million, allowing them to regain compliance with Nasdaq Listing Rule 5550(b)(1) as of December 1, 2025. For context on the operational burn this financing is meant to cover, net cash used in operating activities for the first nine months of 2025 was $5.9 million.

Finance: draft 13-week cash view by Friday.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Customer Segments

Large pharmaceutical and biotech companies seeking to replenish pipelines.

Predictive Oncology Inc. is exploring partnership opportunities with major biopharmaceutical firms to leverage its artificial intelligence and machine learning platform for drug repurposing. The company has already developed a registry for repurposing abandoned drugs, identifying 3 compounds for further exploration in colon and breast cancer indications.

Oncologists and clinicians focused on gynecological and ovarian cancers.

The ChemoFx®, validated flagship live cell drug response assay, is being prepared for aggressive market expansion in the U.S. and a de novo launch in Europe. This assay initially focuses on ovarian and other gynecological cancers to help determine effective chemotherapies, eliminating the current trial-and-error approach.

Global enterprises requiring decentralized, high-demand GPU compute power.

Predictive Oncology Inc. initiated a digital asset treasury strategy focused on ATH, the native utility token of the Aethir network, to function as an operator on the Aethir ecosystem. This allows the company to satisfy enterprise demand for compute through its Strategic Compute Reserve. The company received aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of locked and unlocked ATH with an aggregate notional value of approximately $292.7 million pursuant to private placements supporting this strategy. As of November 10, 2025, the Company held approximately 5.70 billion ATH, with a market value of approximately $152.8 million. The PEDAL platform, which utilizes these capabilities, achieves 92% tumor response prediction accuracy.

Non-profit organizations focused on drug repurposing, like Every Cure.

The company's AI/ML platform is instrumental in identifying new uses for abandoned or discontinued drugs for novel cancer treatments. Predictive Oncology Inc. has developed a portfolio of promising candidates that may potentially be repurposed for additional or alternative indications.

Key metrics related to Predictive Oncology Inc. (POAI) customer-facing offerings as of late 2025:

The company's strategic focus areas for customer engagement include:

• Leveraging AI/ML for drug discovery and development.
• Expanding ChemoFx® availability in the U.S. and Europe.
• Monetizing AI infrastructure through enterprise deployments.
• Developing systems to utilize ATH tokens for revenue generation.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Cost Structure

You're looking at the hard numbers driving Predictive Oncology Inc.'s expenses as of late 2025. The cost structure is clearly bifurcated between traditional operational expenses and the significant impact of the new digital asset strategy.

The General and Administrative expenses were high for the third quarter of 2025, totaling $2.6 million for the three months ended September 30, 2025. This compares to $1.5 million in the same period in 2024. This increase was driven by specific cost components.

The core scientific and development spending, categorized as Operations, research, and development expense, was $528,557 for the three months ended September 30, 2025. This was largely flat compared to $535,236 in the comparable period in 2024.

The most significant financial event impacting the income statement for the quarter was the non-cash charge related to the digital asset treasury strategy. Predictive Oncology Inc. recorded a loss on derivative instruments of $74.4 million in Q3 2025, which is directly tied to the valuation of the ATH token holdings.

Here's a quick look at the key reported operating expenses for Q3 2025:

The increase in General and Administrative expenses was specifically attributed to higher spending in two areas:

• Increased legal fees.
• Increased stock-based compensation expense due to restricted stock units granted to employees, directors, and consultants.

Maintaining the core drug discovery infrastructure represents a fixed cost base. This includes the physical assets supporting the AI platform:

• Costs associated with maintaining the biobank, which holds more than 150,000 assay-capable heterogenous human tumor samples.
• Costs for the wholly owned CLIA lab facility.

Predictive Oncology Inc. (POAI) - Canvas Business Model: Revenue Streams

You're looking at the top line for Predictive Oncology Inc. (POAI) as of late 2025, and honestly, the picture is dominated by the strategic pivot. While the foundational streams-fees from AI-driven drug discovery services and platform licensing-are still part of the overall business, the current reported revenue is quite minimal, suggesting these services haven't scaled to drive significant top-line growth yet. The ChemoFx® drug response assay, which is key to their biobank, also represents a potential revenue source, but specific figures aren't broken out in the latest reports.

The major focus for future revenue generation is clearly the new digital asset strategy. Predictive Oncology Inc. is building out its Strategic Compute Reserve, intending to monetize this via staking and GPU rentals on the Aethir network. They are targeting a high single-digit yield on their ATH tokens by 2026, so this is definitely a forward-looking stream, not one contributing materially to the current numbers.

Here's the quick math on the realized revenue from continuing operations through the third quarter of 2025. The numbers show the current state before the compute monetization is expected to kick in.

To be fair, that Q3 2025 operating revenue of $3,618 was described as minimal and nearly flat year-over-year. The total revenue for the nine months ended September 30, 2025, at $116,610, is up from $76,020 in the prior year period, which is a positive trend, even if the absolute dollar amounts are small relative to the company's asset base.

The streams that underpin the current, albeit small, revenue include:

• AI-driven drug discovery service fees.
• Platform licensing revenue.
• Sales related to the ChemoFx® assay.

Finance: draft 13-week cash view by Friday.